Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-931 relative bioavailability, food effect, and gastric pH modification study in advanced solid tumors
NL-OMON45823Phase 1Completed
- Sponsor
- Takeda
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of simurosertib in Nonhematologic neoplasms, sponsored by Takeda. Primary endpoints: Relative bioavailability based on Cmax, Relative bioavailability based on AUClast and 8 more. Started Apr 2019; status: completed.
02
Drugs
simurosertib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON45823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45823.